Sofosbuvir and velpatasvir

(Epclusa®)

Sofosbuvir and velpatasvir

Drug updated on 11/13/2023

Dosage FormTablet (oral; sofosbuvir/velpatasvir: 400 mg/100 mg, 200 mg/50 mg); Pellets (oral; sofosbuvir/velpatasvir: 200 mg/50 mg, 150 mg/37.5 mg)
Drug ClassCombination of antivirals
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
  • For the treatment of adult and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection with decompensated cirrhosis in combination with ribavirin.

Product Monograph / Prescribing Information

Document TitleYearSource
Epclusa (sofosbuvir and velpatasvir) Prescribing Information.2022Gilead Sciences, Inc., Foster City, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines